

Tel: +4021-317.11.00 Fax: +4021-316.34.97

www.anm.ro

CERTIFICATE OF A PHARMACEUTICAL PRODUCT¹

This certificate conforms to the format recommended by the World Health Organization (explanatory notes are attached)

No. of Certificate: 7804

Exporting (certifying) country: ROMANIA

Importing (requesting) country: MOLDOVA

1. Name, dosage form and strength of the product:

Hepatect CP 50 UI/ml soluție perfuzabilă - name for Romania Hepatect CP 50 IU/ml solution for infusion - name for Moldova

1.1. Active ingredient(s)² and amount(s) per unit dose³:

Human piasma protein	30 mg	30 mg
of which		
Immunoglobulin G		≥96 %
HBs antibodies		50 IU

For complete composition including excipients, see attached ⁴.

1.2.Is this product licensed to be placed on the market for use in the exporting country?⁵

☑ Yes □ No

1.3.Is this product actually on the market in the exporting country?

☑ Yes □ No

If the answer to 1.2. is **yes**, continue with section 2A and omit section 2B. If the answer to 1.2 is **no**, omit section 2A and continue with section $2B^6$.

2.A.1. Marketing Authorisation number⁷: 7349/2015/01-02-03-04

Date of Marketing Authorisation: 30 Jnauary 2015



Tel: +4021-317.11.00 Fax: +4021-316.34.97

www.anm.ro

2.A.2. Product licence holder (name and address):

Name: Biotest Pharma GmbH

Address: Landsteinerstrasse 5, 63303 Dreieich, Germany

2. A.3. Status of product licence holder8:

a/b/c

Manufacturer involved in the manufacture, batch testing (except for pyrogen testing), filling, labeling, and packaging of the finished product

Name: Biotest AG

Address: Landsteiner strasse 5, D-63303 Dreieich, Germany

Manufacturers involved in pyrogen testing

Name: Labor LS SE & Co. KG

Address: Mangelsfeld 4, 5, 6, D-97708 Bad Bocklet-Großenbrach, Germany

Name: Charles River Laboratories Ireland Limited Address: Carrentrila, Ballina, Co. Mayo, Ireland

Manufacturer involved in batch release of the finished product

Name: Biotest Pharma GmbH

Address: Landsteiner strasse 5, D-63303 Dreieich, Germany

- A.3.1 For categories b and c the name and address of the manufacturer producing the dosage form is⁹:
- 2. A.4. Is a summary basis for approval appended?¹⁰

2. A.5. Is the attached, officially approved product information complete and consonent with the licence?¹¹

The applicant assumes the whole responsability for the accuracy of the translation of the text from Romanian into English.

2.A.6. Applicant for certificate, if different from licence holder (name and address)¹²: Yes

Name: Prisum Heathcare SRL

Address: 17 General Gheorghe Manu Street, Office No. 1, Sector 1, Postal Code 031216,

Bucharest, Romania



7, AV. Sanatescu St, Sector 1, 011478 Bucharest Tel: +4021-317.11.00

Fax: +4021-316.34.97

www.anm.ro

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced:

☐ Yes ☐ No ☐ ☐ Not Applicable

- 3.1. Periodicity of routine inspections (years): -
- 3.2. Has the manufacture of this type of dosage form been inspected?

☑ Yes □ No

3.3. Do the facilities and operations conform to GMP as recommended by the World Health Organization?¹⁵

☑ Yes ☐ No ☐ Not Applicable

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product?¹⁶

☑ Yes □ No

Address of certifying authority:

48 Av. Sanatescu Street, sector 1, 011478 Bucharest - Romania

Telephone Number: + 0040-021-317 11 02

Fax Number: + 0040-021-316 34 97

E-mail: www.anm.ro

Name of authorized person: Elena Valeria BRODEALĂ

Signature:

Stamp and date:

23. SEP. 2025



Tel: +4021-317.11.00 Fax: +4021-316.34.97

www.anm.ro

Complete composition:

One ml of solution for infusion contains:	
Human plasma protein	50 mg
of which	
immunoglobulin G	≥96 %
HBs antibodies	50 IU
Glycine	300 μmol
Water for injections	up to 1 ml



Tel: +4021-317.11.00 Fax: +4021-316.34.97

www.anm.ro

Explanatory notes

- ¹ This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.
- ² Use, whenever possible, International Nonproprietary Names (INNs) or national onproprietary names.
- ³ The formula (complete composition) of the dosage form should be given on the certificate or be appended.
- ⁴ Details of quantitative composition are preferred but their provision is subject to the agreement of the product-licence holder.
- ⁵ When applicable, append details of any restriction applied to the sale, distribution or administration of the product that is specified in the product licence.
 - ⁶ Sections 2A and 2B are mutually exclusive.
 - ⁷ Indicate, when applicable, if the licence is provisional, or the product has not yet been approved.
 - ⁸ Specify whether the person responsible for placing the product on the market:
 - (a) manufactures the dosage form;
 - (b) packages and/or labels a dosage form manufactured by an independent company; or
 - (c) is involved in none of the above.
- ⁹ This information can only be provided with the consent of the product-licence holder or, in the case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product licence. If the production site is changed, the licence has to be updated or it is no longer valid.
- ¹⁰ This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed.